52 results about "Bacterial pneumonia" patented technology

The invention provides a deep learning algorithm-based classification method of bacterial pneumonia and viral pneumonia in children. According to the method, a source data set is manually labeled; onthe basis of the combination of a full convolutional network semantic segmentation algorithm and a convolutional neural network algorithm, the full convolutional network semantic segmentation algorithm is adopted to perform lung region foreground segmentation on an image so as to obtain a region of interest, the extracted region of interest is inputted to a convolutional neural network model so asto train a classifier, and therefore, the category of an unknown chest X-ray image can be predicted, and the high-dimensional features of the region of interest are extracted; and a traditional imageprocessing method is adopted to extract the low-dimensional features of the region of interest; and the high-dimensional features and the low-dimensional features are used to train a non-linear classifier; and the category of the unknown X-ray image is predicted, and the type of the pneumonia of a patient can be judged. Since a main component analysis algorithm is used to perform dimensionality reduction on the features, and therefore, the amount of calculation can be reduced; and the features which have been subjected to mixed dimensionality reduction are inputted into the nonlinear classifier, and the category of the unknown X-ray image can be predicted.

The present invention provides methods for treating a bacterial infection and/or bacterial airway colonization in a subject by administering via pulmonary administration an effective amount of fosfomycin as the only active pharmaceutical ingredient. Methods of the present invention are useful in treating bacterial pneumonia infection of any type and/or airway colonization, cystic fibrosis with bacterial infection and/or bacterial lung and/or airway colonization.

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

The objective of the present invention is to allow a hydrogen gas which has a gas mixture concentration of over 4% to be breathed in safely, and to reduce the amount of use of hydrogen gas, which is dangerous, and increase utilization efficiency of the hydrogen gas. The objective of the present invention is also to impart an auxiliary role to a device in the treatment of patients suffering from viral or bacterial pneumonia using hydrogen gas. A hydrogen gas mixture breathing device and a related system employ an intrinsically safe structure and a safety system which prevent occurrence of explosions. A detonation flame arrester, etc. are installed where necessary to provide against electrostatic explosions, etc., and to protect a user's lung function from explosion flames. In addition, a device for supplying aerosol in which a hydroxyl radical is dissolved is also installed, and operating time and volume are appropriately adjusted under the supervision of a professional. Depending on the circumstances, the content of the aerosol is changed to microdroplets that comprise a bivalent iron ion or monovalent copper ion. Suction of a hydrogen-rich gas mixture and suction of the aerosol take place alternatively according to a program and not simultaneously.

The present invention relates to a use of a pharmaceutical composition in the manufacture of medicament for treating related diseases caused by endotoxemia. The pharmaceutical composition comprises 3-methyl-1-phenyl-2-pyrazolin-5-one or pharmaceutically acceptable salt thereof and borneol. The diseases include, but are not limited to, systemic inflammatory response syndrome, sepsis, severe sepsis, septic shock, sepsis related disseminated intravascular coagulation, acute lung injury, acute respiratory distress syndrome, multiple organ failure syndrome, septic brain injury and inflammatory lung injury caused by other reasons, including but not limited to bacterial pneumonia.

The invention provides a multiple quantitative PCR (polymerase chain reaction) kit for quick combined detection of four bacteria difficult to cultivate and identify. The multiple quantitative PCR kit comprises four PCR reaction systems, wherein the four PCR reaction systems comprise AllGlo fluorescence probes and forward and reverse primers aimed at the following four pathogens which cause child bacterial pneumonia and are clinically difficult to cultivate and identify: haemophilus influenza, streptococcus pneumonia, moraxella catarrhalis and legionella pneumophila. According to the multiple quantitative PCR kit, the design is reasonable, the infection of the four pathogens, clinically difficult to cultivate and identify, of child bacterial pneumonia can be easily, conveniently, quickly and parallelly detected in a reaction tube at the same time, the situation that four bacteria are detected at the same time through single-tube PCR is achieved, quantitative detection is achieved, the kit is easy and quick to operate, high in sensitivity, good in specificity and repeatability, accurate and reliable in result, early specific diagnosis, prevention and treatment can be provided for patients suffering from infantile pneumonia according to the bacterial infection titer, and the kit has great clinical practicability for interdicting an infection source, reducing infection or mixed infection of the four bacteria and monitoring the clinical curative effect.

The invention discloses an algorithm improvement of biomimetic pattern recognition in imaging pneumonia discrimination. A healthy X-ray film, a viral pneumonia X-ray film and a bacterial pneumonia X-ray film are normalized into experimental images with the same size; the experimental image I after the normalization of the healthy X-ray film image is input into a convolutional neural network to extract an image feature vector; wherein the convolutional neural network comprises a convolutional layer, a pooling layer and a full connection layer. The image feature vector extraction method comprises the steps of A, carrying out convolution on an experimental image I and a convolution kernel, and outputting a result through an activation function to form a feature map 01 of the convolutional layer; carrying out convolution on the feature map 01 and a next convolution kernel, and outputting a result through an activation function to form a feature map 02 of a convolution layer; and the feature map 02 enters a pooling layer as an input image.

The invention discloses an application of heterocyclic compounds in preparation of medicines for treating pneumonia, and relates to the technical field of biomedicine. According to the application ofthe heterocyclic compounds in the preparation of the medicines for treating the pneumonia provided by the invention, the heterocyclic compounds have anti-pneumonia activity, wherein the pneumonia includes but is not limited to viral pneumonia, bacterial pneumonia, mycoplasma pneumonia, and chlamydia pneumonia. The anti-pneumonia pharmacological activity of the structurally modified and transformedheterocyclic compounds is tested, the pharmacological activity of the compounds is tested in multiple pneumonia models, and data of anti-pneumonia activity are provided to confirm that the heterocyclic compounds all have excellent anti-pneumonia activity, that is, the heterocyclic compounds with antipneumonia activity are screened out, so that a novel skeleton can be provided for screening a novel compound for treating the pneumonia, and a theoretical foundation is laid for development of a novel lead compounds.

The invention provides a traditional Chinese medicine preparation for treating bacterial pneumonia and a preparation method thereof. The traditional Chinese medicine preparation comprises the following active pharmaceutical ingredients: twig and leaf of taperleaf japanese spiraea, psychotria siamica, winged laggera herb, banyan leaves, swamp cudweed herb, scarlet swertia herb, autumn elaeagnus root leaf and fruit, ligustrum sinense, hupeh bauhinia root, Tibet goldenray root, common euscaphis fruit or seed, rhizome of coronarious gingerlily, root of procumbent indian mallow, farges decaisnea root and rheum delavayi franch. The beneficial effects of the invention are as follows: the traditional Chinese medicine preparation provided by the invention is safe and convenient to use and is used for treating bacterial pneumonia in combination with traditional methods of Western medicine, the treatment effect is better, and the traditional Chinese medicine preparation takes effect quickly without toxic or side effect; and meanwhile, adverse effects of Western medicine can be eliminated or reduced, and the preparation technology is simple.

The invention provides an application of licorice flavonoids in preparing antitussives for treating acute and chronic cough caused by a plurality of reasons. The related acute and chronic cough comprises cough symptoms caused by various diseases such as acute and chronic tracheitis, asthma, chronic obstructive disease of lung, idiopathic pulmonary fibrosis, tuberculosis, bacterial pneumonia, bronchiectasis and the like. The licorice flavonoids extracted from liquorice proves to have very strong effect in preventing cough according to pharmacological tests; drug potency thereof is similar to the drug potency of codein in narcotic antitussive; the function mechanism analyses indicate that the licorice flavonoids plays the role of preventing cough through the non-narcotic nerve centre. In addition, the licorice flavonoids extracted from natural plants can also be prepared into health food. The invention solves the problem that the non-narcotic potent antitussives are badly needed, provides a non-narcotic potent antitussives which has fine social and economical benefits.

The invention discloses an application of pulsatilla saponin B4 in preparation of a drug for treating/preventing bacterial pneumonia, induced by klebsiella pneumoniae, of mammals including human being. The pulsatilla saponin B4 has a protecting function on bacterial pneumonia induced by klebsiella pneumoniae, a protecting mechanism can be related to reduction of the content of inflammatory factorsIL-6, IL-1beta and TNF-alpha, the content of MPO, IL-6 and TNF-alpha in lung tissue and the number of neutrophile granulocyte and leukocyte in plasma, and the pulsatilla saponin B4 for injection hasa better effect than a positive drug.

The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains and cocktails thereof, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.

The invention provides a macrolide and carbostyril heterocomplex. The macrolide and carbostyril heterocomplex is characterized by comprising compounds shown in the formula I and the formula II, or thecompounds shown in the formula I and the formula II and salt formed by inorganic acid or organic acid and accepted by pharmacy, the macrolide and carbostyril heterocomplex can better adapt to industrial production and has good activity of resisting sensitive bacteria and drug-resistance bacteria on clinically common streptococcus pneumoniae, staphylococcus aureus, streptococcus pyogenes, catarrhmoraxella catarrhalis, haemophilus influenza and other pathogenic bacteria which are capable of resisting erythrocin, and clinical bacterial pneumonia or pneumonia caused by other microorganisms (suchas mycoplasma, legionella and the like) and other tissue infections can be effectively treated.

The invention relates to a novel clinical application of minor radix buplenri granules. The invention further discloses an application of the minor radix buplenri granules or the minor radix buplenrigranules and amikacin in preparation of drugs for preventing and treating carbapenem-resistant klebsiella pneumoniae infection. It is found that the minor radix buplenri granules can be combined withthe amikacin in antibiotics to improve the antibacterial effect on CRKP, have the sensitization effect and can serve as a natural antibiotic sensitizer. The combined use of the minor radix buplenri granules and the amikacin can enhance the clinical treatment on the CRKP infection, and especially has good antibacterial effect and sensitization effect on bacterial pneumonia caused by the CRKP.

The invention relates to an application of a compound acetylshikonin in preparation of a medicine for resisting lung inflammatory factor storm, namely an inhibition effect of acetylshikonin on mouse acute lung injury and inflammatory factor storm induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein. The compound acetylshikonin can inhibit inflammatory factors induced by polyinosinic-cytidylic acid and SARS-CoV-2 spinous process protein, obviously inhibits expression of interleukin IL-6 in inflammatory reaction, and can be further applied to research and development of drugs for treating or preventing lung inflammation. The acetylshikonin is suitable for treating lung inflammatory factor storm and acute lung injury caused by viral pneumonia, bacterial pneumonia, mycoplasma pneumonia and the like.

The invention discloses a traditional Chinese medicine composition for adjuvant therapy of senile bacterial pneumonia. The traditional Chinese medicine composition is prepared from the following raw materials: salviae miltiorrhizae, ginkgo leaves, herba leonuri, shikonin, cornu bubali, puerarin, muskroot-like semiaquilegia root, aristolochia, concha meretricis seu cyclinae, paederia scandens and hawthorn. The traditional Chinese medicine composition decoction disclosed by the invention is adopted to treat 50 cases of patients and compare with a control group in treatment effect. The result shows that the IL-1, IL-6 and TNF-alpha contents of two groups of patients are reduced (P is smaller than or equal to 0.1) in comparison with that before treatment; the reduction range of a treatment group is greater than that of the control group (P is smaller than 0.5); the total effective rate of the treatment group is 90.00%; the total effective rate of the control group is 72.00%; and the total effective rate of the treatment group is obviously superior to that of the control group (P is smaller than 0.05). According to the traditional Chinese medicine composition for adjuvant therapy of senile bacterial pneumonia, disclosed by the invention, excessive release of an inflammatory medium can be restrained; excessive inflammatory response of the organism is reduced; and the curative effect of adjuvant therapy of senile bacterial pneumonia is significant.

The invention discloses liquid medicine for preventing and treating lung diseases, which is prepared from the following raw materials in parts by weight: 13-15 parts of radix bupleuri, 13-15 parts of radix scutellariae, 5-8 parts of red dates, 8-10 parts of fresh ginger, 13-15 parts of felwort, 13-15 parts of golden cypress, 13-15 parts of liquorice, 10-12 parts of poria cocos, 5 parts of dry powder and a proper amount of purified water. The preparation is simple, and the preparation process has no added chemical substances, the medicinal properties are mild, no side effect is generated, and the product can play a special effect in preventing pneumonia caused by new coronavirus of lung diseases, bacterial pneumonia, herpes pneumonia and pneumonia caused by varicella virus.